Ashvattha Therapeutics, Inc.

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers	Healthy Volunteers	Active, not recruiting	Phase 1	2026-08-27	NCT07370155
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME	diabetic macular edema	Active, not recruiting	Phase 2	2025-05-04	NCT05387837
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers	Alzheimer disease, CNS demyelinating autoimmune disease, Nutritional and Metabolic Diseases, Parkinson disease, TDP-43 proteinopathy, amyotrophic lateral sclerosis, autoimmune disease, autoimmune disorder of the nervous system, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, dementia, demyelinating disease, immune system disorder, metabolic disease, motor neuron disorder, movement disorder, multiple sclerosis, nervous system disorder, neurodegenerative disease, neuromuscular disease, parkinsonian disorder, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, synucleinopathy, tauopathy	Recruiting	Phase 1 / Phase 2	2025-05-02	NCT05395624

Clinical trials